Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

BACKGROUND: We performed a pooled analysis of the COMPARZ study assessing efficacy and safety of pazopanib versus sunitinib in treatment-naïve Chinese patients with locally advanced and/or metastatic renal cell carcinoma (a/mRCC). METHODS: In the COMPARZ study, patients were randomized (1:1) to rece...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Main Authors: Sheng, Xinan, Jin, Jie, He, Zhisong, Huang, Yiran, Zhou, Aiping, Wang, Jinwan, Ren, Xiubao, Ye, Dingwei, Zhang, Xu, Qin, Shukui, Zhou, Fangjian, Wang, Binhui, Guo, Jun
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2020
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7071746/
https://ncbi.nlm.nih.gov/pubmed/32171288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6708-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares